ArticleAntiviral research2024
Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
Open access · greenAbstract read
In one paragraph
Article in Antiviral research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Disulfide bond formation between Cys22 and Cys44 in SARS-CoV-2 main protease.Bioorganic & medicinal chemistry letters · 2026Article
- Article
- From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrum.Nature communications · 2026Article
- Regioselective multicomponent synthesis of α-boryl ureas: discovery of a potent main protease inhibitor.Organic & biomolecular chemistry · 2026Article
- Access toACS organic & inorganic Au · 2025Article
- Sequential Optimization Approach Toward an Azapeptide-Based SARS-CoV-2 Main Protease Inhibitor.Archiv der Pharmazie · 2025Article
- Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Azapeptide-Based SARS-CoV-2 Main Protease Inhibitors: Design, Synthesis, Enzyme Inhibition, Structural Determination, and Antiviral Activity.Journal of medicinal chemistry · 2025Article
- Review
- SARS-CoV-2 Main Protease Inhibitors That Leverage Unique Interactions with the Solvent Exposed S3 Site of the Enzyme.ACS medicinal chemistry letters · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 1 country.
Kaustav KhatuaTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Yugendar R AlugubelliTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Kai S YangTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Veerabhadra R VulupalaTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Lauren R BlankenshipTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Demonta ColemanTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Sandeep AtlaTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Sankar P ChakiDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.
Zhi Zachary GengTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Xinyu R MaTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Jing XiaoTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Peng-Hsun ChenTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Chia-Chuan D ChoTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Shivangi SharmaTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Erol C VatanseverTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Yuying MaTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Ge YuTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA.
Benjamin W NeumanDepartment of Biology, Texas A&M University, College Station, TX 77843, USA; Texas A&M Global Health Research Complex, Texas A&M University, College Station, TX 77843, USA; Health Science Centre, Department of Molecular Pathogenesis and Immunology, Texas A&M University, College Station, TX 77843, USA.
Shiqing XuTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA; Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, TX 77843, USA. Electronic address: shiqing.xu@tamu.edu.
Wenshe Ray LiuTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77854, USA; Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, TX 77843, USA; Institute of Biosciences and Technology and Department of Translational Medical Sciences, College of Medicine, Texas A&M University, Houston, TX 77030, USA; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA; Department of Cell Biology and Genetics, College of Medicine, Texas A&M University, College Station, TX 77843, USA. Electronic address: wsliu2007@tamu.edu.
Texas A&M University · USTexas A&M Health Science Center · US
Funding
Use of the Noncanonical Amino Acid Mutagenesis Technique in Combination with Other Approaches to Study Functions of Posttranslational Lysine Modifications in ProteinsR35GM145351 · NIGMS · TEXAS A&M UNIVERSITY · PI Wenshe Ray Liu · 2022 to 2026
$2.6MDevelopment of fluorogenic and chemiluminogenic main protease substrates for cellular and in vivo imaging of SARS-CoV-2R21EB032983 · NIBIB · TEXAS A&M UNIVERSITY · PI LIU, WENSHE RAY · 2022 to 2023
$411kThe Development of Reversible Covalent PROTAC Technology as a New Anti-COVID-19 StrategyR21AI164088 · NIAID · TEXAS A&M UNIVERSITY · PI XU, SHIQING · 2021 to 2022
$406kNIAID NIH HHS R21 AI164088NIBIB NIH HHS R21 EB032983NIGMS NIH HHS R35 GM145351
Abstract
The main protease (M
Indexed as
Coronavirus 3C ProteasesCOVID-19SARS-CoV-2Antiviral AgentsCysteineCysteine EndopeptidasesHumansProtease InhibitorsViral Nonstructural Proteins3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesCysteineCysteine EndopeptidasesProtease InhibitorsViral Nonstructural ProteinsAzapeptideCovalent inhibitorCOVID-19Main proteaseSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.